Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy and has been applied to clinical medicine. However, there are still some problems, including a relatively low response rate, innate mechanisms of resistance against immune checkpoint bloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagawa, Ray, Sakata, Seiji, Gong, Bo, Seto, Yosuke, Takemoto, Ai, Takagi, Satoshi, Ninomiya, Hironori, Yanagitani, Noriko, Nakao, Masayuki, Mun, Mingyon, Uchibori, Ken, Nishio, Makoto, Miyazaki, Yasunari, Shiraishi, Yuichi, Ogawa, Seishi, Kataoka, Keisuke, Fujita, Naoya, Takeuchi, Kengo, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765052/
https://www.ncbi.nlm.nih.gov/pubmed/34874919
http://dx.doi.org/10.1172/jci.insight.153323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765052/
https://www.ncbi.nlm.nih.gov/pubmed/34874919
http://dx.doi.org/10.1172/jci.insight.153323

Ejemplares similares